| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10211916 | Clinical Lymphoma Myeloma and Leukemia | 2018 | 23 Pages |
Abstract
Lirilumab either as a single agent as well as used in combination with azacitidine has clinical activity in patients with MDS. Further studies are needed to confirm our findings.
Related Topics
Health Sciences
Medicine and Dentistry
Anesthesiology and Pain Medicine
Authors
Fevzi Firat Yalniz, Naval Daver, Katayoun Rezvani, Steven Kornblau, Maro Ohanian, Gautam Borthakur, Courtney D. DiNardo, Marina Konopleva, Jan Burger, Yvonne Gasior, Sherry Pierce, Hagop Kantarjian, Guillermo Garcia-Manero,